Takeda to sell select non-core assets in Latin America for $825m
Takeda Pharmaceutical has agreed to sell a portfolio of select non-core products exclusively in Latin America to Brazilian firm Hypera…
Latest Gastroenterology
-
7 months
-
7 months
-
11 months
-
11 months
-
7 months
-
7 months
-
11 months
-
11 months
Takeda’s SC Entyvio meets primary endpoint in Crohn’s Disease
At the European Crohn’s and Colitis Organization (ECCO) congress in Vienna, Austria, Takeda announced the subcutaneous (SC) formulation of Entyvio…
Latest News
View More
Takeda to sell select non-core assets in Latin America for $825m
Takeda Pharmaceutical has agreed to sell a portfolio of select non-core products exclusively in Latin America to Brazilian firm Hypera Pharma for $825m. The deal…
Takeda’s SC Entyvio meets primary endpoint in Crohn’s Disease
At the European Crohn’s and Colitis Organization (ECCO) congress in Vienna, Austria, Takeda announced the subcutaneous (SC) formulation of Entyvio (vedolizumab) met its primary endpoint…
Company A-Z
View More
Latest Content
View MoreDevelopment and Production of the Respimat® Reuseable Inhaler Housing Module
Boehringer Ingelheim commissioned Gerresheimer to develop and produce on a large scale the housing module for the new generation of…
Technology Partners
Developed to nurture an ecosystem that digitises the workforce, Nymi unites a complete set of benefits aimed at onboarding teams…
Quality Statement
Nymi executed a Quality Management System (QMS) that aligns with its consumer demands and leads the development of products and…
Solution Overview
Healthcare industries struggle to deliver the advantages of digital transformation (DX), as commonplace solutions entail trade-offs between security, compliance, and…